This finding was likewise reported by Oelsner et al
In addition, semaglutide works in a glucose-dependent way
Until Wegovys MASH indication, patients with F2F3 fibrosis lacked any FDAapproved pharmacologic therapy targeting steatohepatitis resolution and fibrosis improvement, relying primarily on lifestyle modification and bariatric surgery. Against this background, semaglutides ability to deliver sustained doubledigit percentage weight loss, improve cardiometabolic markers, reduce MACE, and favorably modify histologic endpoints in MASH positions Wegovy as a versatile agent across cardiometabolic care pathways, provided its risks and limitations are fully understood and respected
Only experienced dermatologists, plastic surgeons, or endocrinologists with a deep understanding of both the science and lifestyle factors can tailor treatment appropriately
Guo X, Lei M, Zhao J, Wu M, Ren Z, Yang X, Ouyang C, Liu X, Liu C, Chen Q
The GLP-1 Effect: Market Penetration In the UK, 4.2 million adultsnearly 1 in 10had recently used a GLP-1 medication or expressed interest in doing so as of early 2025 Two in five overweight Britons (38%) express interest in using GLP-1s for weight loss when informed about the drugs Across Europe, the GLP-1 market is valued at 9.62 billion in 2025, with robust growth expected due to rising obesity and diabetes rates, improved access, and strong healthcare infrastructure in markets like Germany, France, and the UK Social acceptance is rising, and insurance coverage is likely to expand, further accelerating adoption
